A Three-Part Open Label Titration, Open Label Randomized Crossover, and Double Observer Single-Blind, Superiority Trial of APL-130277 compared to S.C. Apomorphine in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations
Phase of Trial: Phase III
Latest Information Update: 23 May 2017
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 19 May 2017 Status changed from planning to recruiting.
- 23 Sep 2016 New trial record
- 31 Aug 2016 According to a Sunovion Pharmaceuticals media release, this study is expected to be initiated in the fourth quarter of 2016.